Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Valion Bio (TIVC) Total Non-Current Liabilities (2024 - 2025)

Valion Bio has reported Total Non-Current Liabilities over the past 2 years, most recently at $7.4 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 2617.65% year-over-year to $7.4 million; the TTM value through Dec 2025 reached $7.4 million, up 2617.65%, while the annual FY2025 figure was $7.4 million, 2617.65% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $7.4 million at Valion Bio, up from $272000.0 in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $7.4 million in Q4 2025 and troughed at $272000.0 in Q4 2024.